Multi-Objective Engineering of Fibrin-Selective Thrombolytic Proteases with Enhanced Biocatalytic Efficiency and Inhibition Resistance
This study presents a multi-objective engineering framework that successfully designed Brnoteplase, a next-generation thrombolytic protease with enhanced fibrin selectivity, inhibition resistance, and catalytic efficiency, demonstrating superior therapeutic efficacy and safety in vivo compared to current FDA-approved variants.